Read More Pharma Industry News Lupin collaborates with AbbVie for $977m MALT1 inhibitor program targeting hematological cancers Indian pharmaceutical company Lupin has entered a landmark agreement to out-license its MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation… bypharmanewsdailyDecember 25, 2018